News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Policy
Appeal Ruling Forces NICE Rethink on Celgene’s Vidaza for MDS
July 27, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Pharmatimes.com -- Patients in the UK with myelodysplastic syndromes will be celebrating news that the National Institute for Health and Clinical Excellence has been ordered to reassess Celgene’s Vidaza for the National Health Service.
Twitter
LinkedIn
Facebook
Email
Print
Legal
MORE ON THIS TOPIC
China
FDA raises bar for foreign site inspections as China trials surge
September 2, 2026
·
4 min read
·
Heather McKenzie
Regulatory
Tavneos no longer available for new patients in UK as Amgen awaits FDA hearing
September 2, 2026
·
2 min read
·
Tristan Manalac
Drug pricing
9 midsize drugmakers climb aboard Trump’s MFN train
September 1, 2026
·
2 min read
·
Tristan Manalac
Legal
Biomarin nabs big royalties in achondroplasia patent settlement with Ascendis
August 31, 2026
·
2 min read
·
Annalee Armstrong
